scholarly journals Direct‐acting antivirals for HCV treatment in older patients: A systematic review and meta‐analysis

2019 ◽  
Vol 26 (11) ◽  
pp. 1249-1256 ◽  
Author(s):  
Rosanna Villani ◽  
Matteo Monami ◽  
Francesca Di Cosimo ◽  
Gilda Fioravanti ◽  
Edoardo Mannucci ◽  
...  
Keyword(s):  
Systematic Review ◽  
Older Patients ◽  
Meta Analysis ◽  
Direct Acting Antivirals ◽  
Hcv Treatment ◽  
Direct Acting

scholarly journals Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0229143 ◽  
Author(s):  
Rodolfo Castro ◽  
Hugo Perazzo ◽  
Letícia Artilles Mello Mendonça de Araujo ◽  
Isabella Gonçalves Gutierres ◽  
Beatriz Grinsztejn ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Direct Acting Antivirals ◽  
Direct Acting

Efficacy and safety of direct‐acting antivirals for hepatitis C in the elderly: A systematic review and meta‐analysis

2019 ◽  
Vol 39 (9) ◽  
pp. 1652-1660 ◽  
Author(s):  
Marcus M. Mücke ◽  
Eva Herrmann ◽  
Victoria T. Mücke ◽  
Christiana Graf ◽  
Stefan Zeuzem ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Meta Analysis ◽  
The Elderly ◽  
Efficacy And Safety ◽  
Direct Acting Antivirals ◽  
Direct Acting

Can Ribavirin be Avoided in the Management of Hepatitis C Genotype 3 Patients When Treated With Direct Acting Antivirals? A Systematic Review and Meta-Analysis

2017 ◽  
Vol 112 ◽  
pp. S559
Author(s):  
Muhammad Ali Khan ◽  
George Cholankeril ◽  
Chiranjeevi Gadiparthi ◽  
Mohammad Siddiqui ◽  
Khwaja F. Haq ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Direct Acting Antivirals ◽  
Genotype 3 ◽  
Direct Acting

scholarly journals Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (8) ◽  
pp. 1694
Author(s):  
Leonardo Frazzoni ◽  
Usama Sikandar ◽  
Flavio Metelli ◽  
Sinan Sadalla ◽  
Giuseppe Mazzella ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Random Effect ◽  
Complete Response ◽  
Direct Acting Antivirals ◽  
Direct Acting ◽  
Hcc Recurrence

Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet. Aim: To assess the risk of HCC recurrence after DAA therapy for hepatitis C virus (HCV). Methods: A systematic review across PubMed, Scopus and Scholar up to November 2020, including full-text studies that assessed the pattern of HCC recurrence after DAA therapy for HCV. Random-effect meta-analysis and univariable metaregression were applied to obtain pooled estimates for proportions and relative risk (RR) and variables influential for the outcome, respectively. Results: Thirty-one studies with 2957 patients were included. Overall, 30% (CI, 26–34%) of the patients with a history of HCC experienced HCC recurrence after DAA therapy, at mean time intervals ranging from 4 to 21 months. This result increased when going from European studies (23%, CI, 17–28%) to US studies (34%, CI, 30–38%), to Egyptian studies (37%, CI, 27–47%), and to Asian studies (33%, CI, 27–40%). Sixty-eight percent (CI, 45–91%) of recurrent HCCs developed within 6 months of follow-up since DAA treatment, among the eight studies providing stratified data. Among the studies providing head-to-head comparisons, the HCC recurrence risk was significantly lower after DAA therapy than IFN (RR, 0.64; CI, 0.51–0.81), and after DAA therapy than no intervention (RR, 0.68; CI, 0.49–0.94). Conclusions: The recurrence of HCC after DAA is not negligible, being higher soon after the end of treatment and among non-European countries. DAA therapy seems to reduce the risk of HCC recurrence compared to an IFN regimen and no intervention.

Risk of HCC in HCV Related Cirrhosis After HCV Clearance with Direct Acting Antivirals: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 152 (5) ◽  
pp. S1163
Author(s):  
Supannee Rassameehiran ◽  
Rashmee Patil ◽  
Ruchi Patel ◽  
Gagan K. Sood
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Direct Acting Antivirals ◽  
Direct Acting

scholarly journals Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Rosanna Villani ◽  
Francesca Di Cosimo ◽  
Antonino Davide Romano ◽  
Moris Sangineto ◽  
Gaetano Serviddio
Keyword(s):  
Systematic Review ◽  
Lipid Profile ◽  
Total Cholesterol ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Hdl Cholesterol ◽  
Treatment Completion ◽  
Direct Acting Antivirals ◽  
Pooled Data ◽  
Direct Acting

AbstractAlthough direct-acting antivirals are very effective and safe drugs, several authors have reported the alteration of lipid profile during and after anti-HCV therapy suggesting a potential impact on the risk of cardiovascular events. We performed a systematic review and meta-analysis of observational studies to investigate the magnitude and temporal trend of lipid profile changes in DAA treated patients. All selected studies included data on lipid profile before starting therapy and at least one follow-up assessment during or after antiviral treatment. We identified 14 studies (N = 1537 patients) after removing duplicates. Pooled data showed an increase in total cholesterol 4 weeks after starting therapy (+ 15.86 mg/dl; 95% CI + 9.68 to 22.05; p < 0.001) and 12 weeks after treatment completion (+ 17.05 mg/dl; 95% CI + 11.24 to 22.85; p < 0.001). LDL trend was similar to the total cholesterol change in overall analysis. A mean increase in HDL-cholesterol of 3.36 mg/dl (95% CI + 0.92 to 5.79; p = 0.07) was observed after 12 weeks of treatment, whereas at SVR24 HDL difference was + 4.34 mg/dl (95% CI + 1.40 to 7.28; p = 0.004).Triglycerides did not show significant changes during treatment and after treatment completion. DAAs induce mild lipid changes in chronic hepatitis C patients treated with DAAs, which may persist after treatment completion.

Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals

2015 ◽  
Vol 20 (1) ◽  
pp. 58-66 ◽  
Author(s):  
Parth Patel ◽  
Kunal Malik ◽  
Karthik Krishnamurthy
Keyword(s):  
Systematic Review ◽  
Chronic Hepatitis ◽  
Relative Risk ◽  
Adverse Events ◽  
Meta Analysis ◽  
Pegylated Interferon ◽  
Direct Acting Antivirals ◽  
Incidence Risk ◽  
Direct Acting ◽  
Chronic Hepatitis C Patients

Background: Direct-acting antivirals (DAAs) are known to present with additional dermatological events over pegylated-interferon/ribavirin (Peg-IFN/RBV). Objective: A systematic review and meta-analysis was conducted to assess the incidence/risk of cutaneous adverse events (AEs) for simeprevir, sofosbuvir, ABT450/r-ombitasvir, dasabuvir, ledipasvir, daclatasvir, and asunaprevir. Methods: The databases searched included PubMed, Clinicaltrials.gov, and Clinicaloptions.com. Data on telaprevir and boceprevir were obtained from a previous study. Results: The incidences of cutaneous AEs were 34.3% (95% CI 18.4%-54.8%) for the old DAAs + Peg-IFN/RBV, 22.0% (95% CI 17.9%-26.8%) for the new DAAs + Peg-IFN/RBV, 9.8% (95% CI 8.6%-11.2%) for the DAAs + RBV, and 3.8% (95% CI 2.4%-6.1%) for DAAs only. Simeprevir + Peg-IFN/RBV was associated with an increased relative risk over Peg-IFN/RBV; RR = 1.319 (95% CI 1.026-1.697). Conclusion: Dermatological events are still an important issue for many of the new DAAs. Appropriate monitoring, management, and patient education are needed to minimize AEs and achieve HCV cure.

Sign in / Sign up

Export Citation Format

Share Document